| Field | Specification |
|---|---|
| Alternative names | ABBV-399 |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Form | Liquid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Telisotuzumab vedotin (ABBV-399, Teliso-V) is an anti-c-Met antibody-drug conjugate composed of the anti-c-Met monoclonal antibody Telisotuzumab (ABT-700) linked to Monomethyl Auristatin E. It exerts antitumor activity with acceptable toxicity in vivo and can be used for non-small cell lung cancer (NSCLC) research[1][2][3]. It is supplied as a colorless to light yellow liquid with an average molecular weight of 145000 g/mol.
Physical & Chemical Properties
| CAS Number | 1714088-51-3 |
|---|---|
| Molecular Weight | 145000 g/mol (average) |
| Appearance | Liquid |
| Color | Colorless to light yellow |
| Signaling Pathway | Antibody-Drug Conjugate/ADC Related; Protein Tyrosine Kinase/RTK; Cytoskeleton; Cell Cycle/DNA Damage |
| Storage | -80°C, protect from light. |
| Shipping | Shipping with dry ice. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
In tumor cell lines with high c-Met expression or MET amplification, Telisotuzumab vedotin (ABBV-399) shows potent cytotoxicity that depends on a threshold level of target expression rather than on inhibition of MET signaling[3].
In Vivo
Telisotuzumab vedotin (ABBV-399) effectively suppresses tumor growth in xenograft models that are resistant to other c-Met inhibitors, and overcomes resistance to small molecule MET inhibitors[3].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer. Cell Rep Med 2026 Apr 21;7(4):102688. PMID: 41856115
HRA00129-C004, a Novel c-Met Antibody-Drug Conjugate (ADC), Exerts Encouraging Anti-Tumor Activities and Favorable Safety Profiles. Mol Cancer Ther 2025 Oct 30. PMID: 41166693
bioRxiv. 2026 Jul 20.
